Brought to you by:
Surgical societies respond to updated pulmonary embolism clinical practice guidelines
In a recent editorial, stakeholders responded to the exclusion of vascular surgical societies from participating in developing updated clinical practice guidelines for the management of acute pulmonary embolism from the American Heart Association (AHA) and the American College of Cardiology…
PERT, AI and the rise of thrombectomy devices: ‘PERT leads to more advanced thrombectomy removal therapies, lower hospital stays’
The increasing sophistication of the device space for the treatment of pulmonary embolism (PE) aligned with advances in the deployment of pulmonary embolism response teams (PERTs) are among factors leading to notable improvements in care, according to leading vascular surgeon…
Interim RAPID-PE study reveals ‘excellent’ safety data in first 50 patients
Prespecified interim analysis data from the first 50 patients in RAPID-PE have demonstrated “excellent safety” and “remarkably efficient lab times” in patients receiving on-the-table pharmacomechanical lysis without any post-procedure infusion with the Bashir endovascular catheter (Thrombolex) for the treatment of…
STORM-PE finds mechanical thrombectomy superior to anticoagulation alone
The use of mechanical thrombectomy, specifically computer-assisted vacuum thrombectomy (CAVT) using the 16Fr Lightning Flash system (Penumbra), with anticoagulation achieves superior reduction in right heart strain compared to anticoagulation therapy alone in patients with acute intermediate-high-risk pulmonary embolism (PE). This…
Imperative Care announces FDA clearance for Symphony thrombectomy system
Imperative Care has today announced Food and Drug Administration (FDA) 510(k) clearance of its Symphony thrombectomy system to treat pulmonary embolism (PE). This clearance expands the use of Symphony—previously for the treatment of venous thrombosis—to now include PE, providing a…
RESCUE II results on Thrombolex’s Bashir endovascular catheter for PE published
Thrombolex recently announced the publication of RESCUE-II study results in JACC: Advances. The RESCUE-II study was a single-centre, prospective study evaluating the safety and feasibility of on-the-table (OTT) pharmacomechanical lysis (PML) without postprocedural infusion when treating patients with acute intermediate-risk…
Penumbra’s STORM-PE randomized trial completes enrollment
Penumbra has announced the completion of enrollment in the STORM-PE clinical trial. The pivotal, prospective, multicenter randomized controlled trial enrolled 100 patients to evaluate computer assisted vacuum thrombectomy (CAVT) using Penumbra’s Lightning Flash plus anticoagulation versus anticoagulation alone for the treatment…
Aventus thrombectomy system gains FDA clearance for PE treatment
Inquis Medical has announced that its Aventus thrombectomy system has received 510(k) clearance from the US Food and Drug Administration (FDA) for an expanded indication to treat pulmonary embolism (PE). The Aventus System is a next-generation mechanical thrombectomy platform developed…
Experts to examine ‘evolving landscape’ of vascular intervention in PE management
A number of topics relating to pulmonary embolism (PE) management—including lytic therapy versus thrombectomy, risk stratification and device selection—will feature this afternoon during an educational session. Taking place from 3:15–4.45 p.m. on the Second Floor (Room 217–219) at the 2025…
Inquis Medical’s Aventus thrombectomy system found safe and effective for patients with PE
Inquis Medical recently announced results from its AVENTUS trial evaluating the safety and efficacy of the company’s Aventus thrombectomy system. The results were presented by Jun Li, MD, from University Hospitals Harrington Heart & Vascular Institute in Cleveland, the trial’s…